How to Tell If a Weight Loss Clinic Works: What a Practice Should Measure About Itself

The harder question is not what a clinic promises a new patient, but what it counts and who quietly falls out of the numbers.

To tell if a weight loss clinic works, look at what it measures about itself. An honest practice can state the average weight change for everyone who started, not only for the people who stayed, how many stopped and why, and what happened to blood pressure, labs and side effects.

Who gets counted, and who quietly disappears?

Someone starts in March. By the second dose she feels queasy, and by late April she has stopped answering the scheduling texts. Come December she is not in the year-end spreadsheet. Nobody deleted her. She stopped generating weigh-ins.

That is how an advertised average ends up describing only the patients who stayed. Treatment goes badly for some people, and those are the people most likely to leave. It is a mechanism, not a motive.

Trials handle it with intent to treat: everyone randomized stays in the analysis, finished or not. A practice can copy that without a statistician. Count every patient who got a first prescription. Report weight change at three, six and twelve months. For anyone who left, carry the last weight forward. The result is lower than a billboard number and far easier to defend.

Why does the denominator matter more than the average?

The denominator is the whole claim. An average built on the patients still active at twelve months describes a subgroup. An average built on everyone who started describes the practice.

Trials describe study conditions. In the STEP program (NEJM 2021), semaglutide 2.4 mg averaged 14.9 percent of body weight over 68 weeks alongside lifestyle changes, and about one in three participants reached 20 percent or more. In SURMOUNT-1 (NEJM 2022), tirzepatide at the highest studied dose averaged about 20.9 percent over 72 weeks. Both programs studied the FDA-approved brand medications; compounded semaglutide and compounded tirzepatide were not studied in them. Results vary by individual, and those percentages describe a study population rather than any clinic's own patients.

What besides weight tells you the care is working?

Weight is the loudest measure available and, alone, among the least informative. Early on I raised doses on a fixed calendar, because a calendar is easy to explain. Enough patients told me the nausea began the week after each step that I changed how I titrate.

Beyond the scale, a short list is worth tracking, some of it on patient report rather than measured in a room:

• Blood pressure and lipids at baseline and repeated, which in telehealth means a local draw and a home cuff.
• A1c or fasting insulin in prediabetes or insulin resistance, since the scale and metabolic risk are different things.
• Medications reduced or stopped under supervision.
• Side effects and dose progression: how many settled once titration slowed, and who reached a therapeutic dose.
• How many people were told no, and why. An approval rate near 100 percent can mean the screening happened before the form, in who chose to fill it out, or that the screening is thin.

How should a practice handle the people who stop?

Call them, and ask what happened.

Discontinuation may be the richest data a weight practice generates. Reasons cluster: cost, side effects, results below expectation, a switch to employer-plan brand coverage, a hard year. Cost is a pricing problem. Side effects are usually titration. Expectations get set at the first visit, before anything is prescribed. Publishing that distribution alongside outcomes tells you what no testimonial can, because a testimonial only speaks for the person telling it.

What should a clinic say out loud before anyone calls?

Price is the easiest honesty test, and ours is posted. The initial physician review is $119 one-time, covering the doctor review and the prescription if approved; medication is billed separately. Compounded semaglutide is $499 per 90 days, $166 a month, about $5.50 a day. Compounded tirzepatide starts at $699 per 90 days, $233 a month, about $7.70 a day. The one-month introduction is $199 and covers a physician evaluation plus, only if a prescription is approved and the dispensing pharmacy can fulfill it for the patient's location, one month of compounded semaglutide, with packaging and shipping details confirmed by the pharmacy before fulfillment; if the review finds the patient is not a candidate, the medication portion is refunded and the evaluation fee covers the work performed. Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not identical to the brand versions, and results vary by individual. HSA and FSA funds are accepted, with financing through Cherry, Klarna and Affirm on terms set by the provider.

Dispensing is handled by state-licensed compounding pharmacies operating under section 503A after patient-specific and location-specific verification, and fulfillment happens only when a prescription is approved and the dispensing pharmacy can fulfill it for the patient's location, with packaging and shipping details confirmed by the pharmacy before fulfillment. Brand GLP-1 medications list around $968 to $1,349 a month before manufacturer programs, and many patients qualify for those programs, so a price set beside ours compares neither the same product nor the real cost. Ozempic and Wegovy are trademarks of Novo Nordisk; Mounjaro and Zepbound are trademarks of Eli Lilly. This clinic is not affiliated with or endorsed by either company.

Price says nothing about whether a medicine suits a person, and this class does not suit everyone. Nausea, vomiting, diarrhea, constipation and abdominal pain are the common effects, usually while a dose is rising. Pancreatitis, gallbladder disease and dehydration severe enough to affect the kidneys are less common and more serious. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 rules this class out, and pregnancy is a reason not to start. This article is general education, not a substitute for personal medical advice from your own prescriber.

Our clinic is in Costa Mesa, California. Telehealth, prescribing and shipping depend on where a patient lives, confirmed before any treatment decision. The 2-minute quiz prepares someone for a consultation. It does not determine eligibility and does not guarantee a prescription.

What can a small practice honestly not know about itself?

More than marketing usually admits. There is no control group, so when blood pressure improves, part of that is the medicine, part is the weight, and part is that a physician was paying attention every month. Small samples swing on a few unusual responders.

We also do not know yet how people who stop after six to twelve months in a cash-pay setting compare over years with trial participants who stopped under study conditions. And to be straight about my own house: we do not publish our intent-to-treat average or our discontinuation reasons yet. That reporting is being built.

What would a referring clinician be right to ask?

If you are deciding where to send a patient, these questions tell you quickly how a practice thinks about its results:

• Average weight change at 12 months counting everyone who started, and what share is still in care?
• What share of patients discontinue, and for what reasons?
• Which non-weight measures come back to me, and how fast?
• How many prospective patients were declined last quarter, and why?
• Who reviews the chart when a side effect is reported, and how fast?
• Is there a written taper and maintenance plan when a patient wants to stop?

Accredited surgical programs have reported outcomes through national registries for years, and medical weight-loss practice has not caught up. State the denominator. State the time point. Say who left.

Frequently asked questions

This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.